939-79-7

Usage

Uses

Used in Organic Synthesis:
4-Methyl-3-nitrobenzonitrile is used as a key intermediate in the synthesis of various organic compounds, including (E)-1-(4-cyano-2-nitrophenyl)-2-(4-(4-cyanophenoxy)phenyl)ethene and (E)-1-(4-fluorophenyl)-2-(4-cyano-2-nitrophenyl)ethene. Its unique structure allows it to be a versatile building block for the development of new molecules with potential applications in various fields.
Used in Pharmaceutical Industry:
4-Methyl-3-nitrobenzonitrile is used as a starting material for the synthesis of pharmaceutical compounds. Its reactivity and functional groups make it suitable for the development of new drugs with potential therapeutic applications.
Used in Chemical Research:
4-Methyl-3-nitrobenzonitrile is also used in chemical research to study the properties and reactions of nitro and nitrile groups. It can be employed to investigate the effects of these functional groups on the reactivity and stability of organic molecules, contributing to the advancement of organic chemistry.

InChI:InChI=1/C8H6N2O2/c1-6-2-3-7(5-9)4-8(6)10(11)12/h2-4H,1H3

Upstream product

• 104-85-8 para-methylbenzonitrile 
• 31680-07-6 4-methyl-3-nitrobenzaldehyde 
• 7697-37-2 nitric acid 
• 89-59-8 4-chloro-2-nitrotoluene 
• 151-50-8 potassium cyanide 
• 41252-97-5 4-iodo-2-nitrotoluene 
• 84-58-2 2,3-dicyano-5,6-dichloro-p-benzoquinone 
• 166522-39-0 4-methyl-3-nitro-benzimidic acid methyl ester 
• 153622-00-5 3-Azido-3-(4-methyl-3-nitro-phenyl)-3H-diazirine 
• 153621-94-4 (3-nitro-4-methylphenyl)chlorodiazirine 

Downstream Products

• 61599-55-1 2-nitro-stilbene-4-carbonitrile 
• 7356-11-8 4-methyl-3-nitro-benzoic acid methyl ester 
• 166522-39-0 4-methyl-3-nitro-benzimidic acid methyl ester 
• 61599-62-0 4-(2-benzo[1,3]dioxol-5-yl-vinyl)-3-nitro-benzonitrile 
• 3261-20-9 1.3-bis-(2-nitro-4-cyano-trans-styryl)-benzene 
• 96-98-0 4-methyl-3-nitrobenzoic acid 
• 19013-11-7 4-methyl-3-nitrobenzamide 
• 60710-80-7 5-cyano-2-methylaniline 
• 860572-86-7 4'-methyl-2-nitro-stilbene-4-carbonitrile 
• 2695-69-4 4,4-(1E,1E)-2,2-(1,4-phenylene)-bis(ethene-2,1-diyl)bis(3-nitrobenzonitrile) 
• 61599-61-9 4'-acetylamino-2-nitro-stilbene-4-carbonitrile 
• 65199-95-3 4'-hydroxy-2-nitro-stilbene-4-carbonitrile 
• 15331-81-4 4'-methoxy-2-nitro-stilbene-4-carbonitrile 
• 61599-63-1 4'-hydroxy-3'-methoxy-2-nitro-stilbene-4-carbonitrile 

Relevant academic research and scientific papers

Mild Darzens Annulations for the Assembly of Trifluoromethylthiolated (SCF3) Aziridine and Cyclopropane Structures

We report mild new annulation approaches to trisubstituted trifluoromethylthiolated (SCF3) aziridines and cyclopropanes via Darzens inspired protocols. The products of these anionic annulations, rarely studied previously, possess attractive features rendering them valuable building blocks for synthesis platforms. In this study, trisubstituted acetophenone nucleophiles bearing SCF3 and bromine substituents in their α position were shown to undergo [2 + 1] annulations with vinyl ketones and tosyl-protected imines under mild reaction conditions.

INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS

The present invention relates to compounds which specifically inhibit bacterial DNA Gyrase and can be used for the treatment of respiratory tract infections.

Copper- and silver-mediated cyanation of aryl iodides using ddq as cyanide source

A new copper and silver-mediated cyanation of aryl iodides with DDQ as a cyanide source is achieved, providing nitriles with good yields. This new approach represents a safe method leading to aryl nitriles. A new copper and silver-mediated cyanation of aryl iodides with DDQ as a cyanide source is achieved.

One pot synthesis of nitriles from aldehydes and hydroxylamine hydrochloride using ferrous sulphate in DMF under reflux condition

A rapid and facile one pot synthesis of nitrile has been carried out in high yields from the corresponding aldehydes and hydroxylamine hydrochloride in the presence of anhydrous ferrous sulphate and DMF under reflux condition.

Quinoxaline compounds

Certain amidophenyl-sulfonylamino-quinoxaline compounds are CCK2 modulators useful in the treatment of CCK2 mediated diseases.

Progress in the palladium-catalyzed cyanation of aryl chlorides

The development of new palladium catalysts for the cyanation of various aryl and heteroaryl chlorides is described. The combination of amine co-catalysts with chelating phosphine ligands, for example, 1,4-bis(diphenylphosphino)butane (dppb) or 1,5-bis(diphenylphosphino)pentane (dpppe), allows an efficient cyanation of chloroarenes with simple potassium cyanide. General palladium-catalyzed cyanation of nonactivated and deactivated chloroarenes is possible for the first time. Studies of the oxidative addition of aryl halides to palladium triphenylphosphine complexes in the presence and absence of amines suggest that the co-catalyst is capable of preventing catalyst deactivation caused by the presence of excess cyanide ions in solution.

Nitration of moderately deactivated arenes with nitrogen dioxide and molecular oxygen under neutral conditions. Zeolite-induced enhancement of regioselectivity and reversal of isomer ratios

In the presence of zeolites, moderately deactivated arenes such as 1-nitronaphthalene, naphthonitriles, and methylated benzonitriles can be smoothly nitrated at room temperature by the combined action of nitrogen dioxide and molecular oxygen. The regioselectivity is considerably improved as compared with the conventional nitration methodology based on nitric and sulfuric acids. In some cases, the minor isomer became favoured to a significant extent, resulting in the reversal of ordinary isomer ratios of nitration products.

Non-covalent thrombin inhibitors featuring P3-heterocycles with P1-monocyclic arginine surrogates

Investigations on P2-P3-heterocyclic dipeptide surrogates directed towards identification of an orally bioavailable thrombin inhibitor led us to pursue novel classes of achiral, non-covalent P1-arginine derivatives. The design, synthesis, and biological activity of inhibitors NC1-NC30 that feature three classes of monocyclic P1-arginine surrogates will be disclosed: (1) (hetero)aromatic amidines, amines and hydroxyamidines, (2) 2-aminopyrazines, and (3) 2-aminopyrimidines and 2-aminotetrahydropyrimidines.

Piperazine compounds and medicinal use thereof

The present invention relates to a piperazine compound of the formula wherein R1and R2are each hydrogen, halogen, lower alkyl, lower alkoxy, amino, substituted amino, nitro, hydroxy or cyano, R3, R4and R5are each hydrogen, halogen, lower alkyl, lower alkoxy, nitro, amino, substituted amino or hydroxy, R6and R7are each hydrogen, lower alkyl, lower alkyl substituted by halogen, aralkyl, acyl or lower acyl substituted by halogen, R8and R9are each hydrogen or lower alkyl, Y is lower alkylene and the like, and ring A is phenyl, pyrimidyl, thiazolyl, pyridyl, pyrazyl or imidazolyl, a pharmaceutically acceptable salt thereof and pharmaceutical agents containing these compounds. The compound of the present invention has superior TNF-α production inhibitory effect and/or IL-10 production promoting effect, and, since it is free of or shows only strikingly reduced expression of an effect on the central nervous system, the compound is useful as a highly safe and superior TNF-α production inhibitor an/or IL-10 production promoter and is useful as an agent for the prophylaxis or treatment of various diseases caused by abnormal TNF-α production, diseases curable with IL-10, such as chronic inflammatory diseases, acute inflammatory diseases, inflammatory diseases due to infection, autoimmune diseases, allergic diseases, and TNF-α mediated diseases.

Thrombin inhibitors, the preparation and use thereof

Compounds of the formula and the salts thereof with physiologically tolerated acids and the stereoisomers thereof, in which the substituents have the meanings stated in the description, are described. Also disclosed are intermediates for their preparation. The compounds are suitable for controlling diseases.